Contreras J, Pérez N, González R, Ontivero E, López M
Department of Chemistry, National Center for Scientific Research, Havana, Cuba.
Arzneimittelforschung. 1998 Mar;48(3):259-62.
The relative bioavailability of theophylline (CAS 58-55-9) was evaluated after a single dose administration of two sustained-release theophylline tablet formulations: Controfilina-200 as test preparation (test) and a commonly used reference preparation (reference). The design of the study was crossover in twelve healthy volunteers, with a series of two experimental sessions. The two sessions were carried out at weekly intervals. Theophylline concentrations were measured by HPLC (high performance liquid chromatography). The bioavailability was compared using the parameters: AUC0-infinity (area under the concentration-time curve), Cmax (maximal theophylline concentration), tmax (time after drug intake at which the maximal concentration is reached) and Cmax/AUC0-infinity. The results of this study indicated that the new generic sustained-release tablet and the reference are bioequivalent when the same dosage is administered.
在单次给药两种缓释茶碱片剂制剂后,评估了茶碱(CAS 58-55-9)的相对生物利用度:将Controfilina-200作为试验制剂(试验品),并与常用的参比制剂(参比品)进行比较。该研究设计为12名健康志愿者的交叉试验,包括一系列两个实验阶段。两个阶段每周进行一次。通过高效液相色谱法(HPLC)测定茶碱浓度。使用以下参数比较生物利用度:AUC0-无穷大(浓度-时间曲线下面积)、Cmax(最大茶碱浓度)、tmax(达到最大浓度的药物摄入后时间)以及Cmax/AUC0-无穷大。该研究结果表明,当给予相同剂量时,新的通用型缓释片剂与参比品具有生物等效性。